RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Quan Capital, a Shanghai healthcare investor, filed to raise $300 million for its second fund. In August 2017, the firm closed its first fund with $150 million. Globally, Quan seeks investments in biopharmas with potentially breakthrough products, while in China it targets companies with innovative services for China’s drug development sector. The company has very close ties to Shanghai’s Zai Lab: Quan is headed by Dr. Samantha Du, founder and CEO of Zai, and Dr. Marietta Wu is a Managing Director at Quan and also a Founder of Zai.
Source: China Biotoday
